Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Xu, Miao  [Clear All Filters]
Journal Article
Hong J, Cheng Y-S, Yang S, Swaroop M, Xu M, Beers J, Zou J, Huang W, Marugan JJ, Cai X, et al. Corrigendum to "iPS-derived neural stem cells for disease modeling and evaluation of therapeutics for mucopolysaccharidosis type II" [Exp. Cell Res. 412, Issue 1, 1 March 2022, 113007]. Exp Cell Res. 2023;433(2):113808.
Huang W, Cheng Y-S, Yang S, Swaroop M, Xu M, Huang W, Zheng W. Disease modeling for Mucopolysaccharidosis type IIIB using patient derived induced pluripotent stem cells. Exp Cell Res. 2021:112785.
Yin W, Mao X, Xu M, Chen M, Xue M, Su N, Yuan S, Liu Q. Epigenetic regulation in the commitment of progenitor cells during retinal development and regeneration. Differentiation. 2023.
Xu X, Pradhan M, Xu M, Cheng Y-S, Beers J, Linask KL, Lin Y, Zheng W, Zou J. Four induced pluripotent stem cell lines (TRNDi021-C, TRNDi023-D, TRNDi024-D and TRNDi025-A) generated from fibroblasts of four healthy individuals. Stem Cell Res. 2020;49:102011.
Li R, Pradhan M, Xu M, Baskfield A, Farkhondeh A, Cheng Y-S, Beers J, Zou J, Liu C, Might M, et al. Generation of an induced pluripotent stem cell line (TRNDi002-B) from a patient carrying compound heterozygous p.Q208X and p.G310G mutations in the NGLY1 gene. Stem Cell Res. 2018;34:101362.
Hong J, Xu M, Li R, Cheng Y-S, Kouznetsova J, Beers J, Liu C, Zou J, Zheng W. Generation of an induced pluripotent stem cell line (TRNDi008-A) from a Hunter syndrome patient carrying a hemizygous 208insC mutation in the IDS gene. Stem Cell Res. 2019;37:101451.
Pavlinov I, Farkhondeh A, Yang S, Xu M, Cheng Y-S, Beers J, Zou J, Liu C, Might M, Rodems S, et al. Generation of two gene corrected human isogenic iPSC lines (NCATS-CL6104 and NCATS-CL6105) from a patient line (NCATS-CL6103) carrying a homozygous p.R401X mutation in the NGLY1 gene using CRISPR/Cas9. Stem Cell Res. 2021;56:102554.
Pradhan M, Farkhondeh A, Cheng Y-S, Xu M, Beers J, Zou J, Liu C, Might M, Rodems S, Baumgärtel K, et al. An induced pluripotent stem cell line (NCATS-CL9075) from a patient carrying compound heterozygote mutations, p.R390P and p.L318P, in the NGLY1 gene. Stem Cell Res. 2021;54:102400.
Huang W, Xu M, Li R, Baskfield A, Kouznetsova J, Beers J, Zou J, Liu C, Zheng W. An induced pluripotent stem cell line (TRNDi006-A) from a MPS IIIB patient carrying homozygous mutation of p.Glu153Lys in the NAGLU gene. Stem Cell Res. 2019;37:101427.
Hong J, Cheng Y-S, Yang S, Swaroop M, Xu M, Beers J, Zou J, Huang W, Marugan JJ, Cai X, et al. iPS-derived neural stem cells for disease modeling and evaluation of therapeutics for mucopolysaccharidosis type II. Exp Cell Res. 2022:113007.
Cheng Y-S, Xu M, Chen G, Beers J, Chen CZ, Liu C, Zou J, Zheng W. A Protocol for Culture and Characterization of Human Induced Pluripotent Stem Cells After Induction. Curr Protoc. 2023;3(8):e866.
Ma J, Ning Y-N, Xu M, Hou Y, Wang N, Hou X-Y, Yu Y-Y, Li H, He W-D, Shao L-L, et al. Thalidomide corrects impaired mesenchymal stem cell function in inducing tolerogenic DCs in patients with immune thrombocytopenia. Blood. 2013.
Owusu-Ansah K, Pavlinov I, Xu M, Beers J, Chen C, Zheng W, Zou J. Three induced pluripotent stem cell lines (TRNDi033-A, TRNDi034-A, TRNDi035-A) generated from lymphoblasts of three apparently healthy individuals. Stem Cell Res. 2023;71:103135.